Leerink Partnrs Has Positive Outlook of TWST FY2025 Earnings

Key Points

• Leerink Partnrs has improved its FY2025 EPS estimate for Twist Bioscience to ($2.12) per share, up from a previous estimate of ($2.24).
• The company recently reported earnings of ($0.47) per share, surpassing analysts' expectations of ($0.54), with revenue of $96.06 million.
• Multiple analysts have adjusted their price targets for Twist Bioscience, with estimates ranging widely from $33.00 to $50.00, leading to a consensus rating of "Moderate Buy."

Twist Bioscience Corporation (NASDAQ:TWST - Free Report) - Equities researchers at Leerink Partnrs raised their FY2025 EPS estimates for shares of Twist Bioscience in a research note issued to investors on Monday, August 4th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($2.12) per share for the year, up from their prior forecast of ($2.24). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.12) per share. Leerink Partnrs also issued estimates for Twist Bioscience's Q4 2025 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.55) EPS and FY2027 earnings at ($1.13) EPS.

A number of other research analysts have also issued reports on the stock. JPMorgan Chase & Co. reduced their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Robert W. Baird reduced their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Evercore ISI set a $46.00 price target on shares of Twist Bioscience in a research note on Monday. Barclays reduced their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $49.40.

Twist Bioscience Trading Down 5.9%

Twist Bioscience stock opened at $25.90 on Thursday. The company has a quick ratio of 4.24, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The firm has a 50-day moving average price of $34.63 and a two-hundred day moving average price of $38.42. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -17.86 and a beta of 2.36. Twist Bioscience has a 52-week low of $25.63 and a 52-week high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 2,449 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the sale, the chief financial officer directly owned 103,569 shares of the company's stock, valued at $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Patrick John Finn sold 1,877 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $55,840.75. Following the sale, the chief operating officer owned 240,783 shares in the company, valued at $7,163,294.25. This represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,109 shares of company stock valued at $425,962 over the last ninety days. Insiders own 3.01% of the company's stock.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently made changes to their positions in TWST. Versant Capital Management Inc raised its holdings in shares of Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after acquiring an additional 580 shares during the period. GAMMA Investing LLC raised its holdings in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares during the period. Banque Transatlantique SA acquired a new position in Twist Bioscience in the 4th quarter valued at approximately $43,000. GF Fund Management CO. LTD. acquired a new position in Twist Bioscience in the 4th quarter valued at approximately $58,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after buying an additional 302 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.